Figure 2
Figure 2. CD8+ T-cell priming upon administration of Kb-deficient or allogeneic NK-cell targets is highly sensitive. CD8+ T-cell responses upon administration of various doses of Kb-deficient (A,B) or allogeneic (C-D) NK-cell targets. CD8+ T-cell responses were quantified 8 days after immunization by measuring IFN-γ production upon restimulation with OVA257-264 ex vivo (A) or the ability of CD8+ T cells to kill OVA-expressing target cells in vitro (B). (C,D) C57BL/6 mice were either immunized with act-mOVA targets on a mixed H-2b × H-2k (closed bars) or H-2b × H-2d (open bars) background (± SEM; n = 3). (E) Survival of allogeneic C3H/HeN-act-mOVA and β2m-deficient splenocytes in C57BL/6J recipient mice (percentage is calculated from the ratio between β2m-deficient and C57BL/6J cells in β2m-deficient recipients for each day). (F) CD8+ T-cell responses upon administration of 106 allogeneic C3H/HeN.act-mOVA target cells in C57BL/6J control, C57BL/6J-Prf1tm1Sdz, and C57BL/6Jgld/gld recipient mice (n = 6 for each group).

CD8+ T-cell priming upon administration of Kb-deficient or allogeneic NK-cell targets is highly sensitive. CD8+ T-cell responses upon administration of various doses of Kb-deficient (A,B) or allogeneic (C-D) NK-cell targets. CD8+ T-cell responses were quantified 8 days after immunization by measuring IFN-γ production upon restimulation with OVA257-264 ex vivo (A) or the ability of CD8+ T cells to kill OVA-expressing target cells in vitro (B). (C,D) C57BL/6 mice were either immunized with act-mOVA targets on a mixed H-2b × H-2k (closed bars) or H-2b × H-2d (open bars) background (± SEM; n = 3). (E) Survival of allogeneic C3H/HeN-act-mOVA and β2m-deficient splenocytes in C57BL/6J recipient mice (percentage is calculated from the ratio between β2m-deficient and C57BL/6J cells in β2m-deficient recipients for each day). (F) CD8+ T-cell responses upon administration of 106 allogeneic C3H/HeN.act-mOVA target cells in C57BL/6J control, C57BL/6J-Prf1tm1Sdz, and C57BL/6Jgld/gld recipient mice (n = 6 for each group).

Close Modal

or Create an Account

Close Modal
Close Modal